Benznidazole

Generic Name: Benznidazole

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₁₂N_₄O_₃

CAS Number: 22994-85-0

Unique Ingredient Identifier: YC42NRJ1ZD

Background: Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. It is the first treatment made available in the United States for Chagas disease.

Indication: For use in the treatment of Chagas disease in children 2-12 years of age .

Associated Conditions: Chagas' Disease caused by Typanosoma cruzi

Associated Therapies: -

Clinical Trials

A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.

Phase 2

Not yet recruiting

Conditions: Chagas Disease

Interventions: Drug: LXE408
Drug: Benznidazole
Drug: Placebo

First Posted Date: 2024-10-09

Last Posted Date: 2024-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 130

Registration Number: NCT06632600

A Phase 1 Study of the Safety and Tolerability of ICM20 in Adults

Phase 1

Active, not recruiting

Conditions: Safety Issues

Interventions: Drug: ICM20
Drug: Benznidazole

First Posted Date: 2022-08-31

Last Posted Date: 2024-07-17

Lead Sponsor: IC-MedTech Corporation

Target Recruit Count: 13

Registration Number: NCT05523596

Locations: 🇺🇸
Culmore Clinic, Falls Church, Virginia, United States
🇺🇸
Parkway Medical, Glen Burnie, Maryland, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States

Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease

Phase 3

Active, not recruiting

Conditions: Chagas Disease

Interventions: Drug: Benznidazole

First Posted Date: 2019-07-18

Last Posted Date: 2023-08-14

Lead Sponsor: Insud Pharma

Target Recruit Count: 178

Registration Number: NCT04024163

Locations: 🇨🇴
Fundación Salud para el Trópico, Santa Marta, Colombia
🇨🇴
Centro de Atención e Investigación Médica (CAIMED), Yopal, Colombia
🇦🇷
Hospital "Luis Carlos Lagomaggiore", Mendoza, Argentina

and more 6 locations

New Therapies and Biomarkers for Chagas Infection

Phase 2

Completed

Conditions: Trypanosoma Cruzi Infection
Chagas Disease

Interventions: Drug: Benznidazole
Drug: Nifurtimox

First Posted Date: 2019-06-11

Last Posted Date: 2024-07-17

Lead Sponsor: University of Texas, El Paso

Target Recruit Count: 450

Registration Number: NCT03981523

Locations: 🇧🇴
Platform for the Comprehensive Care of Patients with Chagas Disease, Sucre, Bolivia

Pharmacokinetic Drug-Drug Interaction Study

Phase 1

Completed

Conditions: Chagas Disease

Interventions: Drug: Benznidazole
Drug: E1224

First Posted Date: 2019-03-27

Last Posted Date: 2019-03-27

Lead Sponsor: Drugs for Neglected Diseases

Target Recruit Count: 28

Registration Number: NCT03892213

Locations: 🇦🇷
FP Clinical Pharma - Juncal 4484 - 3o piso, Buenos Aires, Argentina

Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age

Phase 3

Recruiting

Conditions: Chagas Disease

Interventions: Drug: Benznidazole
Drug: Placebo Oral Tablet

First Posted Date: 2018-09-14

Last Posted Date: 2024-07-05

Lead Sponsor: Tulane University School of Public Health and Tropical Medicine

Target Recruit Count: 600

Registration Number: NCT03672487

Locations: 🇺🇸
University of California at San Diego, San Diego, California, United States
🇺🇸
Tulane School of Public Health and Tropical Medicine, New Orleans, Louisiana, United States
🇦🇷
Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina

BENDITA BEnznidazole New Doses Improved Treatment and Associations

Phase 2

Conditions: Chagas Disease

Interventions: Drug: Benznidazole
Drug: E1224 Placebo
Drug: E1224
Drug: Benznidazole Placebo

First Posted Date: 2017-12-20

Last Posted Date: 2017-12-20

Lead Sponsor: Drugs for Neglected Diseases

Target Recruit Count: 210

Registration Number: NCT03378661

Locations: 🇧🇴
Plataforma de Atención Integral de Pacientes con Enfermedad de Chagas., Tarija, Bolivia

Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease.

Phase 2

Completed

Conditions: Chagas Disease
Trypanosoma Cruzi Infection

Interventions: Drug: Benznidazole

First Posted Date: 2017-06-19

Last Posted Date: 2023-12-19

Lead Sponsor: Hospital Universitari Vall d'Hebron Research Institute

Target Recruit Count: 238

Registration Number: NCT03191162

Locations: 🇪🇸
Infectious Disease Department Vall d'Hebron Hospital, Barcelona, Spain
🇧🇷
Centro de Pesquisas René Rachou - Fundação Oswaldo Cruz. (FIOCRUZ), Belo Horizonte, Brazil
🇧🇷
Hospital Universitário Clemente de Faria, Montes Claros, Brazil

and more 4 locations

Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial

Phase 3

Completed

Conditions: Chagas Disease

Interventions: Drug: Placebo
Drug: Benznidazole

First Posted Date: 2015-03-11

Last Posted Date: 2015-03-11

Lead Sponsor: Instituto Nacional de Parasitologia Dr. Mario Fatala Chaben

Target Recruit Count: 910

Registration Number: NCT02386358

Locations: 🇦🇷
Instituto Nacional de Parasitología Dr Mario Fatala Chaben, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY)

Phase 2

Conditions: Chagas Disease

Interventions: Drug: Placebo
Drug: Nifurtimox
Drug: Benznidazole

First Posted Date: 2015-02-24

Last Posted Date: 2017-07-21

Lead Sponsor: Universidad Autónoma de Bucaramanga

Target Recruit Count: 500

Registration Number: NCT02369978

Locations: 🇨🇴
Fundación Oftalmológica de Santander - Clínica Ardila Lulle (FOSCAL), Bucaramanga, Santander, Colombia

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy